Biosimilar Nivolumab-Based Combination Therapy in Advanced Oral Cavity Squamous Cell Carcinoma: A Real-World Case Series of Five Patients.

Squamous cell carcinomas of the head and neck (SCCHN) belongs to a biologically aggressive group of malignancies. The salvage options, after failure of the platinum-based therapy and immune checkpoint inhibitors (ICIs), are usually very limited. The regimen comprising oral methotrexate, erlotinib, and celecoxib (OMCT) has been explored as a well-tolerated, low-dose management option. We present through the case series the clinical outcomes of patients who had recurrent, refractory, or locally advanced SCCHN treated with OMCT in combination with low-dose nivolumab for translatable evidence.